Article

IntraLase femtosecond laser approved for sale in Taiwan market

The IntraLase femtosecond laser (IntraLase Corp.) has been approved for sale in Taiwan. Taiwan Hwa-In, IntraLase’s distributor in Hong Kong and Mainland China, will offer the company’s products immediately.

The IntraLase femtosecond laser (IntraLase Corp.) has been approved for sale in Taiwan. Taiwan Hwa-In, IntraLase’s distributor in Hong Kong and Mainland China, will offer the company’s products immediately.

“The added safety of the IntraLase Method in LASIK will provide excellent momentum to drive patient demand in Taiwan, which has a very large number of patients seeking safer and more reliable treatments,” said Jay Hsu, chief executive officer (CEO) of Taiwan Hwa-In.

IntraLase President and CEO Robert J. Palmisano added, “The Taiwanese market represents an exciting opportunity and further demonstrates the global potential of IntraLase technology. We look forward to entering the market and helping Taiwanese practitioners offer clinically proven safety and improved visual outcomes to their patients.”

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times)  ASCRS 2025: Joaquin De Rojas, MD, leverages machine learning model to predict arcuate outcomes
(Image credit: Ophthalmology Times) ASCRS 2025: AnnMarie Hipsley, DPT, PhD, presents VESA for biomechanical simulation of presbyopia progression
Shehzad Batliwala, DO, aka Dr. Shehz, discussed humanitarian ophthalmology and performing refractive surgery in low-resource, high-risk areas at the ASCRS Foundation Symposium.
(Image credit: Ophthalmology Times) ASCRS 2025: Advancing vitreous care with Inder Paul Singh, MD
(Image credit: Ophthalmology Times) The Residency Report: Study provides new insights into USH2A target end points
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
© 2025 MJH Life Sciences

All rights reserved.